MGC028 — Initial data
late 2026
The dose escalation study of MGC028 is ongoing and the Company anticipates providing an update with preliminary clinical results in late 2026.Source filing
MGNX biotech catalysts & pipeline
MACROGENICS INC · Data as of 2026-10-25
Upcoming catalysts
lorigerlimab — Initial data
H1 2027
The Company is enrolling 20 additional patients with clear cell gynecologic cancer (CCGC) at a dose of 3 mg/kg Q3W and anticipates reporting updated study results in the first half of 2027.Source filing
lorigerlimab — Conference presentation
Oct 23–Oct 27
MacroGenics continues the Phase 2 LINNET study of lorigerlimab, with the interim data accepted for poster presentation at the ESMO 2026 Congress.Source filing